Stuart Carter, MD
Cornea and External Diseases Specialist · Allentown, PANPI 1477997682
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 52.2% of the total.
Across 128 payments — averaging $29.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alcon$612
- Sun Pharmaceutical Industries Inc.$207
- Dompe US, Inc.$148
- Bausch & Lomb, A Division Of Bausch Health US, LLC$140
- Tarsus Pharmaceuticals, Inc.$125
- plus $554 from 16 others
What the payments were for
- Food & beverage$3,739100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 68 | $1,953 |
| Alcon | 17 | $612 |
| Sun Pharmaceutical Industries Inc. | 10 | $207 |
| Dompe US, Inc. | 5 | $148 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $140 |
| Tarsus Pharmaceuticals, Inc. | 1 | $125 |
| Glaukos Corporation | 1 | $80 |
| Kala Pharmaceuticals, Inc. | 3 | $72 |
| Shire North American Group Inc | 3 | $61 |
| NEW World Medical,inc. | 2 | $60 |
| Ocular Therapeutix, Inc. | 3 | $54 |
| Oyster Point Pharma, Inc. | 1 | $32 |
| Rayner Intraocular Lenses Limited | 1 | $31 |
| Harrow Eye, LLC | 1 | $22 |
| Biotissue Holdings Inc. | 1 | $21 |
| Bausch & Lomb Americas Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Omeros Corporation | 1 | $18 |
| Sight Sciences, Inc. | 1 | $18 |
| Spark Therapeutics, Inc. | 1 | $17 |
| Eyepoint US, Inc. | 1 | $13 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$489
- RESTASIS$341
- DURYSTA$232
- Hydrus Microstent$137
- XEN GLAUCOMA TREATMENT SYSTEM$125
- XDEMVY$125
- Clareon$120
- VUITY$117
How this compares
Too few cornea and external diseases specialist providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 85 | $108,968 |
| LumiganBimatoprost | 162 | $76,448 |
| Cyclosporine | 83 | $48,394 |
| ProlensaBromfenac Sodium | 66 | $22,986 |
| Difluprednate | 204 | $19,581 |
| XiidraLifitegrast | 14 | $16,314 |
| Bromfenac Sodium | 110 | $14,076 |
| Prednisolone Acetate | 449 | $13,274 |
| MoxifloxacinMoxifloxacin Hcl | 587 | $9,123 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $6,991 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 44 | $6,934 |
| Latanoprost | 422 | $5,439 |
| Brimonidine Tartrate | 45 | $5,239 |
| Timolol Maleate | 117 | $3,115 |
| Travoprost | 11 | $2,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,953 | $192,407272 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $140 | $22,98666 claims |
| Bausch & Lomb Americas Inc.Xiidra | $21 | $16,31414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Allentown
- Brian ShaferPlymouth Meeting$736K
- Giacomina Massaro-GiordanoPhiladelphia$64K
- Hamza PashaCranberry Township$3K
- Kevin ShahWyomissing$3K
- Stephen OrlinPhiladelphia$3K
- Mira AminNorth Wales$2K
- Sabrina MukhtarPittsburgh$2K
- John FiletaLancaster$2K
- Samantha MarekWest Chester$2K
- Jonathan PrimackWyomissing$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.